Research on incident diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture

YE Run-hua; SHI Rui-zi; CAO Dong-dong; YAO Shi-tang; TANG Ren-hai; GAO Jie; XIANG Li-fen; YANG Yue-cheng; WANG Ji-bao; DING Ying-ying; HE Na; DUAN Song

doi:10.16462/j.cnki.zhjbkz.2022.12.002

Volume 26 Issue 12

Dec. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(12): 1371-1378

YE Run-hua, SHI Rui-zi, CAO Dong-dong, YAO Shi-tang, TANG Ren-hai, GAO Jie, XIANG Li-fen, YANG Yue-cheng, WANG Ji-bao, DING Ying-ying, HE Na, DUAN Song. Research on incident diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(12): 1371-1378. doi: 10.16462/j.cnki.zhjbkz.2022.12.002

Citation:

YE Run-hua, SHI Rui-zi, CAO Dong-dong, YAO Shi-tang, TANG Ren-hai, GAO Jie, XIANG Li-fen, YANG Yue-cheng, WANG Ji-bao, DING Ying-ying, HE Na, DUAN Song. Research on incident diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(12): 1371-1378. doi: 10.16462/j.cnki.zhjbkz.2022.12.002

Citation:

YE Run-hua, SHI Rui-zi, CAO Dong-dong, YAO Shi-tang, TANG Ren-hai, GAO Jie, XIANG Li-fen, YANG Yue-cheng, WANG Ji-bao, DING Ying-ying, HE Na, DUAN Song. Research on incident diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(12): 1371-1378. doi: 10.16462/j.cnki.zhjbkz.2022.12.002

PDF( 927 KB)

Research on incident diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture

doi: 10.16462/j.cnki.zhjbkz.2022.12.002

1.
Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
2.
Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
3.
Dehong Dai and Jingpo Autonomous Prefecture People's Hospital, Mangshi 678400, China

YE Run-hua and SHI Rui-zi contributed equally to this article

Funds:

National Science and Technology Major Project of China 2018ZX17021102-004

More Information

Corresponding author: HE Na, E-mail: nhe@fudan.edu.cn; DUAN Song, E-mail: dhduansong@sina.com.cn
Received Date: 2021-11-09
Rev Recd Date: 2022-04-08

Available Online: 2022-12-30

Publish Date: 2022-12-10

Abstract

Abstract

Objective To estimate the cumulative incidence and risk factors of diabetes among HIV/AIDS patients receiving antiretroviral therapy (ART) in Dehong Dai and Jingpo autonomous prefecture (Dehong), Yunnan Province. Methods HIV/AIDS patients without diabetes at baseline (Jul 2017 to Jun 2018) were followed from Jan. 2021 to June 2021. Data of participants were extracted from the National HIV/AIDS antiretroviral therapy database in China. All participants underwent hemoglobin A1c (HbA1c) testing. Diabetes was defined as follow-up HbA1c≥6.5% or the most recent FPG≥7.0 mmol/L. Logistic regression analysis was conducted to evaluate the risk factors of diabetes among HIV/AIDS patients. Results A total of 3 647 HIV/AIDS patients were included in this study, with 51.4% being male and median age of 42 (36, 49) years old. Anti-HCV antibodies were detected in 21.5% of participants. The median time since HIV diagnosis and duration on ART were 12.1 (9.3, 14.6) and 9.3 (7.6, 12.2) years, respectively. The 3-year cumulative incidence of diabetes, HbA1c≥6.5% and PFG≥ 7.0 mmol/L were 6.0%, 2.5% and 5.3%, respectively. Multivariate logistics regression analysis showed that baseline age of ≥50 years, male, HCV-coinfection, elevated TG at baseline, baseline HIV viral load of > 50 copies/ml, baseline use of efavirenz (EFV) were significantly associated with higher risk of incident diabetes. (All P < 0.05). Conclusions HIV/AIDS patients receiving ART in Dehong prefecture are at high risk of diabetes, underscoring needs of targeted prevention and intervention programs in this population.
- HIV,
- Diabetes,
- Cumulative incidence,
- Risk factors

FullText(HTML)

References(17)

References

[1]	Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study[J]. Clin Infect Dis, 2011, 53(11): 1130-1139. DOI: 10.1093/cid/cir626.
[2]	Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy[J]. J Acquir Immune Defic Syndr, 2009, 50(5): 499-505. DOI: 10.1097/QAI.0b013e31819c291b.
[3]	Han WM, Jiamsakul A, Kiertiburanakul S, et al. Diabetes mellitus burden among people living with HIV from the Asia-Pacific region[J]. J Int AIDS Soc, 2019, 22(1): 25236. DOI: 10.1002/jia2.25236.
[4]	马中慧, 高洁, 曹东冬, 等. 德宏傣族景颇族自治州新报告HIV感染者多共病现况研究[J]. 中华疾病控制杂志, 2021, 25(12): 1380-1386. DOI: 10.16462/j.cnki.zhjbkz.2021.12.004. Ma ZH, Gao J, Cao DD, et al. Prevalence and associated factors of multimorbidity among newly reported HIV-positive individuals in Dehong Dai and Jingpo autonomous prefecture[J]. Chin J Dis Control Prev, 2021, 25(12): 1380-1386. DOI: 10.16462/j.cnki.zhjbkz.2021.12.004.
[5]	叶润华, 李静, 姚仕堂, 等. 德宏傣族景颇族自治州抗病毒治疗的HIV/AIDS糖尿病患病率及其相关因素分析[J]. 中华流行病学杂志, 2019, 40(6): 654-659. DOI: 10.3760/cma.j.issn.0254-6450.2019.06.010. Ye RH, Li J, Yao ST, et al. Prevalence and related factors on diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo autonomous prefecture[J]. Chin J Epidemiol, 2019, 40(6): 654-659. DOI: 10.3760/cma.j.issn.0254-6450.2019.06.010.
[6]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344. DOI: 10.19538/j.nk2018040108. Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 edition)[J]. Chin J Prac Intern Med, 2018, 38(4): 292-344. DOI: 10.19538/j.nk2018040108.
[7]	中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-950. DOI: 10.3969/jissn.1000-3614.2016.10.001. Joint Committee for Revised Guidelines for the Prevention and Control of Chinese Adult Dyslipidemia. Guidelines for the prevention and control of Chinese adult dyslipidemia (2016 revised edition)[J]. Chinese Circulaction Journal, 2016, 31(10): 937-950. DOI: 10.3969/jissn.1000-3614.2016.10.001.
[8]	Prioreschi A, Munthali RJ, Soepnel L, et al. Incidence and prevalence of type 2 diabetes mellitus with HIV infection in Africa: a systematic review and meta-analysis[J]. BMJ Open, 2017, 7(3): e013953. DOI: 10.1136/bmjopen-2016-013953.
[9]	Xue H, Wang C, Li Y, et al. Incidence of type 2 diabetes and number of events attributable to abdominal obesity in China: a cohort study[J]. J Diabetes, 2016, 8(2): 190-198. DOI: 10.1111/1753-0407.12273.
[10]	Faurholt-Jepsen D, Olsen MF, Andersen AB, et al. Hyperglycemia and insulin function in antiretroviral treatment-naive HIV patients in Ethiopia: a potential new entity of diabetes in HIV?[J]. AIDS, 2019, 33(10): 1595-1602. DOI: 10.1097/QAD.0000000000002249.
[11]	Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis[J]. Diabetes Metab Res Rev, 2017, 33(6): 10.1002/dmrr. 2902. DOI: 10.1002/dmrr.2902.
[12]	Zicari S, Sessa L, Cotugno N, et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under Long-Term ART[J]. Viruses, 2019, 11(3): 200. DOI: 10.3390/v11030200.
[13]	Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options[J]. J Acquir Immune Defic Syndr. 2008, 49(Suppl 2): 86-92. DOI: 10.1097/QAI.0b013e31818651e6.
[14]	Sinxadi PZ, McIlleron HM, Dave JA, et al. Plasma Efavirenz concentrations are associated with lipid and glucose concentrations[J]. Medicine (Baltimore), 2016, 95(2): e2385. DOI: 10.1097/MD.0000000000002385.
[15]	Noubissi EC, Katte JC, Sobngwi E. Diabetes and HIV[J]. Curr Diab Rep, 2018, 18(11): 125. DOI: 10.1007/s11892-018-1076-3.
[16]	Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review[J]. Lancet Glob Health, 2017, 5(12): 1192-1207. DOI: 10.1016/S2214-109X(17)30375-3.
[17]	Coelho AR, Moreira FA, Santos AC, et al. Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test - which method to choose for the diagnosis?[J]. BMC Infect Dis, 2018, 18(1): 309. DOI: 10.1186/s12879-018-3221-7.